Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type 1 selected

Type

Guidance programme 1 selected

Guidance programme

Showing 1 to 55 of 55

TitleReference numberPublishedLast updated
Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabineTA440
Ixekizumab for treating moderate to severe plaque psoriasisTA442
Obeticholic acid for treating primary biliary cholangitisTA443
Panitumumab in combination with chemotherapy for the treatment of metastatic colorectal cancer (terminated appraisal)TA240
Alectinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (terminated appraisal)TA438
Elotuzumab for previously treated multiple myeloma (terminated appraisal)TA434
Tenofovir alafenamide for treating chronic hepatitis B (terminated appraisal)TA435
Bevacizumab for treating EGFR mutation-positive non-small-cell lung cancer (terminated appraisal)TA436
Ibrutinib with bendamustine and rituximab for treating relapsed or refractory chronic lymphocytic leukaemia after systemic therapy (terminated appraisal)TA437
Ustekinumab for treating active psoriatic arthritisTA340
Ustekinumab for treating moderate to severe plaque psoriasisTA180
Everolimus for advanced renal cell carcinoma after previous treatmentTA432
Apremilast for treating active psoriatic arthritisTA433
Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutationTA429
Sofosbuvir–velpatasvir for treating chronic hepatitis CTA430
Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomibTA427
Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimensTA423
Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancerTA424
Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemiaTA425
Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemiaTA426
Everolimus with exemestane for treating advanced breast cancer after endocrine therapyTA421
Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA422
Ticagrelor for preventing atherothrombotic events after myocardial infarctionTA420
Nivolumab for previously treated advanced renal cell carcinomaTA417
Dapagliflozin in triple therapy for treating type 2 diabetesTA418
Apremilast for treating moderate to severe plaque psoriasisTA419
Dapagliflozin in combination therapy for treating type 2 diabetesTA288
Elbasvir–grazoprevir for treating chronic hepatitis CTA413
Cobimetinib in combination with vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanomaTA414
Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitorTA415
Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusionTA409
Talimogene laherparepvec for treating unresectable metastatic melanomaTA410
Necitumumab for untreated advanced or metastatic squamous non-small-cell lung cancerTA411
Radium-223 dichloride for treating hormone-relapsed prostate cancer with bone metastasesTA412
Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancerTA406
Pegaspargase for treating acute lymphoblastic leukaemiaTA408
Secukinumab for treating active ankylosing spondylitisTA407
Bosutinib for previously treated chronic myeloid leukaemiaTA401
Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatinTA402
Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxelTA391
Ramucirumab for previously treated locally advanced or metastatic non-small-cell lung cancerTA403
Degarelix for treating advanced hormone-dependent prostate cancerTA404
Trifluridine–tipiracil for previously treated metastatic colorectal cancerTA405
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399
Nivolumab in combination with ipilimumab for treating advanced melanomaTA400
Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicatedTA387
Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimenTA259
Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA393
Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemiaTA394
Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancerTA395
Trametinib in combination with dabrafenib for treating unresectable or metastatic melanomaTA396
Adalimumab for treating moderate to severe hidradenitis suppurativaTA392
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetesTA390
Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fractionTA388
Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancerTA389

Results per page

  1. 10
  2. 25
  3. 50
  4. All